Coronary artery disease
Conditions
Interventions
Group of patients treated with coronary intervention-Normal AMR(Part I):NA
Nomal microcirculation resistance group-High AMR(Part I):NA
Normal microcirculatory resistance group(Part II):On the basis of conventional treatment, add 2 capsules of Musk Baoxin Pill orally for 3-6 months
Elevated microcirculation resistance group(Part II):On the basis of conventional treatment, add 2 capsules of Musk Baoxin Pill orally for 3-6 months
Sponsors
Shaoxing Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Part I: Retrospective Trial: Select PCI patients who underwent coronary intervention treatment in our hospital from January 2021 to June 2022, and screen suitable patients for enrollment. Inclusion criteria: 1. Age over 18 years old; 2.DSA images are clear and complete, capable of completing QFR and AMR detection; 3.The follow-up data is basically complete; Part II: Prospective Study The PCI patients who underwent coronary intervention in our hospital from Dec 2024 to Dec 2025 were selected, and suitable patients were selected for enrollment. Inclusion Criteria: 1. Be at least 18 years old; 2.Stable or unstable angina, or acute myocardial infarction, or evidenced asymptomatic myocardial ischemia; 3.Able to understand the trial design and sign a written informed consent form
Exclusion criteria
Exclusion criteria: Part I: Retrospective Trial: Exclusion criteria: 1. Cardiogenic shock or severe heart failure (NYHA = III); 2.Severe impairment of renal function: dialysis status or creatinine clearance rate GFR<45 mL/kg/1.73 m2 (calculated using the Cockcroft Gault formula); 3.Known malignant tumors and severe hematological disorders; Part II: Prospective Studies Exclusion criteria: 1.Cardiogenic shock or severe heart failure (NYHA = III); 2.Severe impairment of renal function: dialysis status or creatinine clearance rate GFR<45 mL/kg/1.73 m2 (calculated using the Cockcroft Gault formula); 3.Known malignant tumors and severe hematological disorders; 4.Life expectancy is less than 1 year; 5.Preparing pregnant women within one year;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiovascular Death (Part I);Heart Failure (Part I);Malignant arrhythmias (Part I); microcirculation resistance index (AMR) ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiovascular Death (Part II);Heart Failure (Part II);Malignant arrhythmias (Part II); | — |
Countries
China
Contacts
Public ContactJianyao Shen
Department of Cardiology, Shaoxing Central Hospital (The Central Affiliated Hospital, Shaoxing University), Shaoxing 312030, Zhejiang,China
Outcome results
None listed